- Home
- GNLX vs PRE Comparison
GNLX vs PRE Comparison
Compare GNLX & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- PRE
- Stock Information
- Founded
- GNLX 2001
- PRE 2014
- Country
- GNLX United States
- PRE Hong Kong
- Employees
- GNLX N/A
- PRE N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- PRE Biotechnology: Laboratory Analytical Instruments
- Sector
- GNLX Health Care
- PRE Industrials
- Exchange
- GNLX Nasdaq
- PRE Nasdaq
- Market Cap
- GNLX 128.0M
- PRE 131.3M
- IPO Year
- GNLX 2023
- PRE N/A
- Fundamental
- Price
- GNLX $7.70
- PRE $13.82
- Analyst Decision
- GNLX Strong Buy
- PRE Buy
- Analyst Count
- GNLX 5
- PRE 1
- Target Price
- GNLX $17.40
- PRE $32.00
- AVG Volume (30 Days)
- GNLX 232.9K
- PRE 175.7K
- Earning Date
- GNLX 11-13-2025
- PRE 11-26-2025
- Dividend Yield
- GNLX N/A
- PRE N/A
- EPS Growth
- GNLX N/A
- PRE N/A
- EPS
- GNLX N/A
- PRE N/A
- Revenue
- GNLX N/A
- PRE $57,051,000.00
- Revenue This Year
- GNLX N/A
- PRE $202.46
- Revenue Next Year
- GNLX N/A
- PRE $103.60
- P/E Ratio
- GNLX N/A
- PRE N/A
- Revenue Growth
- GNLX N/A
- PRE 256.82
- 52 Week Low
- GNLX $1.99
- PRE $3.10
- 52 Week High
- GNLX $8.27
- PRE $17.99
- Technical
- Relative Strength Index (RSI)
- GNLX 73.82
- PRE 49.66
- Support Level
- GNLX $7.05
- PRE $14.50
- Resistance Level
- GNLX $8.26
- PRE $17.84
- Average True Range (ATR)
- GNLX 0.68
- PRE 1.55
- MACD
- GNLX 0.17
- PRE -0.44
- Stochastic Oscillator
- GNLX 82.75
- PRE 30.57
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.